Investigational Drug Information for OPN-375

What is the drug development status for OPN-375?

OPN-375 is an investigational drug.

There have been 8 clinical trials for OPN-375. The most recent clinical trial was a Phase 3 trial, which was initiated on July 28^th 2025.

The most common disease conditions in clinical trials are Nasal Polyps, Sinusitis, and Chronic Disease. The leading clinical trial sponsors are Optinose US Inc. and [disabled in preview].

There are zero US patents protecting this investigational drug and zero international patents.

Summary for OPN-375

US Patents	2,275
International Patents	11,342
US Patent Applications	4,436
WIPO Patent Applications	0
Japanese Patent Applications	2,159
Clinical Trial Progress	Phase 3 (2025-07-28)
Vendors	26

Recent Clinical Trials for OPN-375

Title	Sponsor	Phase
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps	Optinose US Inc.	PHASE3
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Sinusitis Without the Presence of Nasal Polyps	Optinose US Inc.	Phase 3
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps	Optinose US Inc.	Phase 3

See all OPN-375 clinical trials

Clinical Trial Summary for OPN-375

Top disease conditions for OPN-375

Top clinical trial sponsors for OPN-375

See all OPN-375 clinical trials

US Patents for OPN-375

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
OPN-375		Heterocyclic compounds useful in the treatment of disease	Epigen Biosciences, Inc. (San Diego, CA)
OPN-375		11-substituted bile acid derivatives, process for the preparation thereof and use of these compounds as medicaments	Council of Scientific and Industrial Research CSIR
OPN-375		Antibody formulations	Genentech Inc

International Patents for OPN-375

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
OPN-375	Australia	AU2014232383	2033-03-15
OPN-375	Australia	AU2019202731	2033-03-15
OPN-375	Australia	AU2019288275	2033-03-15

OPN-375 Development Update and Market Projection: XHANCE Patent, FDA, and Commercial Outlook

Last updated: September 8, 2026

OPN-375 is Optinose's fluticasone propionate exhalation delivery system, marketed in the United States as XHANCE. The product is no longer an investigational candidate. The FDA approved XHANCE in 2017 for nasal polyps in adults, and expanded its indication in 2023 to chronic rhinosinusitis without nasal polyps. Its commercial opportunity is driven by a large undertreated chronic rhinosinusitis population, but adoption remains constrained by device-based administration, payer controls, specialist prescribing, and generic or authorized-generic risk after patent expiry. [1][2]

The base-case U.S. sales outlook is approximately $100 million to $180 million annually by 2028, assuming continued prescription growth and stable reimbursement. A higher case reaches $250 million or more if Optinose materially expands use in chronic rhinosinusitis without nasal polyps and maintains favorable net pricing.

What is OPN-375 and how does XHANCE work?

OPN-375 combines fluticasone propionate, a corticosteroid, with Optinose's Exhalation Delivery System. The device uses the patient's exhaled breath to move medication into the nasal passages. The delivery approach is intended to reach regions of the nasal cavity that conventional sprays may not adequately treat.

Attribute	OPN-375 / XHANCE
Active ingredient	Fluticasone propionate
Drug class	Intranasal corticosteroid
Delivery system	Exhalation Delivery System
Route	Nasal
Initial FDA approval	2017
Initial indication	Nasal polyps in adults
Expanded indication	Chronic rhinosinusitis without nasal polyps
Commercial company	Optinose, Inc.
Primary market	United States
Development status	Approved and commercial

The product's commercial differentiation is primarily the delivery device, not a new molecular entity. That distinction affects pricing power, patent strategy, generic substitution risk, and manufacturing complexity.

What is the current FDA regulatory status of OPN-375?

The FDA approved XHANCE in March 2017 for the treatment of nasal polyps in adults. The approval was based on the NAVIGATE clinical program, including studies evaluating nasal congestion and other symptoms associated with nasal polyps. [1]

In December 2023, the FDA approved an expanded indication for the treatment of chronic rhinosinusitis without nasal polyps in adults. The supplemental approval broadened the addressable market beyond patients with visible nasal polyps and reduced reliance on a narrower specialty population. [2]

FDA development milestones

Date	Milestone
2015	Late-stage development program for OPN-375 advanced in chronic rhinosinusitis
2017	FDA approval for adult nasal polyps
2018-2022	Commercial expansion in specialty ear, nose and throat practice
2023	FDA approval for chronic rhinosinusitis without nasal polyps
2024 onward	Commercialization of the broader chronic rhinosinusitis label

The expanded label is commercially important because chronic rhinosinusitis without nasal polyps is substantially larger than the nasal-polyp segment. It also places XHANCE in competition with standard intranasal corticosteroids, saline irrigation, antihistamines, oral corticosteroids, sinus surgery, and biologics.

What clinical evidence supports XHANCE?

The principal evidence base consists of trials in chronic rhinosinusitis and nasal polyps. The NAVIGATE I and NAVIGATE II studies evaluated XHANCE in patients with nasal polyps. The ReOpen program supported the expanded chronic rhinosinusitis indication, including patients without nasal polyps. [3][4]

The product's clinical value proposition has four components:

1. Improvement in nasal congestion and obstruction.
2. Reduction in chronic rhinosinusitis symptoms.
3. Potential reduction in the need for escalation to surgery or biologic treatment.
4. Delivery of topical corticosteroid therapy to deeper nasal regions.

The commercial evidence is less straightforward than the regulatory evidence. Physicians must distinguish XHANCE from lower-cost conventional fluticasone sprays, and payers may require failure of generic intranasal corticosteroids before covering the device.

How large is the market for OPN-375?

The U.S. chronic rhinosinusitis market is large, but the immediately addressable market for XHANCE is smaller. Most patients initially receive low-cost medical treatment. XHANCE is more likely to be prescribed for patients with persistent symptoms, inadequate response to standard sprays, prior sinus surgery, or specialist-managed disease.

Addressable-market framework

Market segment	Commercial relevance to XHANCE
Chronic rhinosinusitis without nasal polyps	Largest potential expansion segment
Chronic rhinosinusitis with nasal polyps	Established initial market
Patients with prior sinus surgery	Higher-value target population
Patients failing standard nasal sprays	Most direct substitution opportunity
Severe disease eligible for biologics	Potential steroid-device alternative or step before biologics
Primary-care patients with mild disease	Lower near-term probability of use

The product competes against inexpensive generic corticosteroid sprays. It also competes indirectly against Dupixent, Nucala, and other biologics for severe chronic rhinosinusitis with nasal polyps, although biologics generally target more severe disease and carry much higher costs.

What is the market projection for XHANCE?

The following projection uses a commercial scenario model rather than company guidance. It assumes U.S. sales, gradual uptake following the broader label, net annual revenue per treated patient of approximately $1,500 to $2,500 after discounts, and continued specialist adoption.

Year	Conservative case	Base case	Upside case
2024	$75 million	$90 million	$105 million
2025	$82 million	$105 million	$130 million
2026	$90 million	$125 million	$165 million
2027	$98 million	$150 million	$205 million
2028	$105 million	$175 million	$250 million
2029	$110 million	$195 million	$290 million

Base-case assumptions

The base case assumes:

• Continued growth in prescriptions following the expanded indication.
• Increased use by otolaryngologists and allergy specialists.
• Moderate payer coverage with prior authorization in some plans.
• No major competing device with equivalent delivery characteristics.
• No early generic launch before the core device and formulation patents expire.
• Stable commercial execution by Optinose or a successor commercial partner.

The upside case requires more rapid penetration among chronic rhinosinusitis patients without nasal polyps. It also assumes XHANCE becomes a routine step between conventional sprays and surgery or biologic therapy.

What patents protect OPN-375 and XHANCE?

XHANCE is protected by a combination of drug-device, formulation, delivery-method, and use-related intellectual property. The key protection is the Exhalation Delivery System and its use for delivering corticosteroids into the nasal cavity.

The relevant patent categories include:

• Exhalation-assisted nasal delivery devices.
• Configurations that create pressure or airflow through the nasal passage.
• Drug formulations compatible with the delivery device.
• Methods for treating chronic rhinosinusitis.
• Methods for treating nasal polyps.
• Device components, including mouthpieces, seals, and nasal interfaces.

Patent protection is more complex than protection for a conventional fluticasone nasal spray because a generic applicant would need to address both the active ingredient and the delivery system. However, device complexity does not eliminate generic risk. A competitor could pursue a therapeutically equivalent product with a different device or challenge individual patents through Paragraph IV litigation.

How strong is the patent estate for OPN-375?

The estate is stronger than a conventional intranasal-steroid estate because it is layered across the device and use of the device. Its main strengths are:

• Product differentiation based on delivery mechanics.
• Multiple potential claim categories.
• Clinical labeling tied to chronic rhinosinusitis and nasal polyps.
• Manufacturing and human-factors requirements that increase development complexity.

Its limitations are equally important:

• Fluticasone propionate is a mature, widely available active ingredient.
• The device must demonstrate pharmaceutical equivalence and comparable performance.
• Some method-of-use claims may be vulnerable to inducement or label-carve-out strategies.
• A challenger can attack patent validity, claim scope, written description, enablement, or obviousness.

A definitive patent-expiration analysis requires the current FDA Orange Book listing and the latest USPTO terminal-disclaimer and patent-adjustment data. Public commercial materials do not establish a single reliable loss-of-exclusivity date for every XHANCE protection.

What is the Orange Book status of XHANCE?

XHANCE is an FDA-approved prescription drug-device combination listed in the FDA regulatory framework for approved drug products. The relevant Orange Book analysis should separate:

1. Patents covering the drug product.
2. Patents covering the delivery device.
3. Method-of-use patents.
4. Pediatric exclusivity, if applicable.
5. Patent certifications submitted by abbreviated new drug applicants.

The economic significance of an Orange Book listing depends on whether an ANDA applicant must make a Paragraph IV certification and whether the listed patent is eligible for a 30-month stay following litigation. Device patents that are not properly listed for the drug product may still be asserted in separate patent litigation, but they may not produce the same automatic regulatory stay.

When does OPN-375 lose exclusivity?

OPN-375 has already lost new chemical entity exclusivity because fluticasone propionate is an established active ingredient. Its commercial protection therefore depends mainly on patents, regulatory exclusivity associated with the indication, and the practical difficulty of duplicating the delivery system.

The key loss-of-exclusivity risk is likely to arise in stages:

Protection layer	Risk timing
New chemical entity exclusivity	Not available
Initial nasal-polyp indication	Expired or no longer the principal barrier
Expanded chronic rhinosinusitis indication	Method-of-use protection may remain relevant
Device and delivery patents	Main potential barrier to substitution
Formulation patents	May delay or complicate equivalent product development
Manufacturing know-how	Can raise development cost but does not independently block approval

The commercial impact may begin before complete patent expiry. An ANDA filing, Paragraph IV notice, or competing 505(b)(2) application could reduce expected duration of exclusivity even if final market entry occurs later.

Which companies are challenging OPN-375?

Publicly visible competitive pressure is primarily economic and therapeutic rather than a clearly established biosimilar challenge. Potential challengers include:

• Generic nasal corticosteroid manufacturers.
• Specialty pharmaceutical companies developing nasal delivery devices.
• Companies using 505(b)(2) pathways for differentiated intranasal formulations.
• Manufacturers seeking to develop an equivalent or substitutable fluticasone product.
• Biologic manufacturers competing for severe nasal-polyp patients.

No biosimilar pathway applies to XHANCE because it is a small-molecule corticosteroid product, not a biologic. The principal regulatory threat is an ANDA or 505(b)(2) competitor.

What generic entry risks exist for XHANCE?

Generic entry is technically more difficult than for a conventional nasal spray, but the risk is material.

A competitor would need to address:

• Fluticasone propionate formulation.
• Nasal spray performance.
• Device operation and dose delivery.
• Human-factors requirements.
• Local and systemic exposure.
• Clinical endpoint equivalence.
• Patent certifications.
• Manufacturing consistency.

The most credible entry pathways are:

ANDA pathway

An ANDA applicant would seek approval as therapeutically equivalent to XHANCE. The applicant would need to resolve listed patents, potentially through Paragraph IV litigation. A successful carve-out of patented methods could permit a narrower label.

505(b)(2) pathway

A 505(b)(2) applicant could rely partly on existing fluticasone data while introducing a different device, formulation, or administration method. This route may avoid some development costs but could generate separate patent litigation and labeling disputes.

Device-adjacent competition

A competitor could develop a different exhalation-assisted or pressure-assisted nasal device. Such a product would not necessarily be an automatic substitute, but it could pressure pricing and reimbursement.

What patent litigation affects OPN-375?

The principal litigation risk is expected to involve future ANDA or 505(b)(2) challenges to device, formulation, and method-of-use patents. A reliable current litigation assessment requires docket-level review of federal court filings, Patent Trial and Appeal Board proceedings, FDA patent certifications, and Optinose's latest SEC disclosures.

The most consequential litigation outcomes would be:

• Invalidation of core device claims.
• A finding that the accused product does not infringe.
• A settlement granting an early generic launch date.
• A successful injunction delaying launch.
• A label carve-out allowing limited generic use.
• Inter partes review or post-grant review cancellation of asserted claims.

Are there licensing deals for OPN-375?

Optinose has historically controlled the XHANCE product and its commercial development. The principal commercial question is whether the company retains direct commercialization rights or enters a regional, co-promotion, or strategic transaction.

A licensing transaction could improve market penetration by providing:

• A larger specialty-sales infrastructure.
• Better payer contracting.
• Broader primary-care reach.
• International commercialization capability.
• Capital for post-approval studies.

No major global licensing transaction is necessary to establish the current U.S. product economics. The U.S. market remains the central commercial opportunity.

How does OPN-375 compare with competing treatments?

Treatment	Main advantage	Main limitation relative to XHANCE
Generic fluticasone spray	Low cost and familiarity	Conventional delivery may provide less targeted deposition
Saline irrigation	Low cost and broad use	No corticosteroid unless combined with another product
Sinus surgery	Mechanical relief and access	Invasive, costly, and recurrence is possible
Dupixent	Strong option for severe nasal polyps	High cost and injectable biologic administration
Nucala	Established biologic option	Narrower severe-disease positioning and high cost
XHANCE	Targeted corticosteroid delivery without surgery or injection	Higher cost and device-use burden

XHANCE is best positioned as an intermediate treatment: more differentiated than a standard spray, less invasive than surgery, and less expensive and burdensome than biologic therapy.

What is the investment and revenue exposure?

XHANCE revenue depends on prescription growth, reimbursement, gross-to-net discounts, and the timing of generic entry. Revenue concentration is a material risk because XHANCE is the company's principal commercial product.

The most important operating indicators are:

• New prescription growth.
• Refill persistence.
• Number of active prescribers.
• Prior-authorization approval rates.
• Net realized price.
• Commercial versus government-payer mix.
• Use in chronic rhinosinusitis without nasal polyps.
• Specialty-pharmacy abandonment rates.
• Patent challenges and settlement terms.

A durable revenue ramp requires the expanded indication to produce new treated patients rather than merely shift existing nasal-polyp prescriptions into a broader label.

Key Takeaways

• OPN-375 is the development code for XHANCE, an approved fluticasone propionate exhalation delivery system.
• FDA approval covers adult nasal polyps and chronic rhinosinusitis without nasal polyps.
• The 2023 label expansion materially increased the addressable market.
• The commercial moat is based on delivery technology, formulation, and use patents rather than molecular novelty.
• XHANCE has no biosimilar risk; generic and 505(b)(2) competition are the relevant threats.
• Base-case U.S. sales could reach approximately $175 million by 2028, with a wider range of $105 million to $250 million.
• The largest commercial risks are payer restrictions, slow specialist adoption, conventional generic sprays, and patent challenges.
• The strongest growth opportunity is use in chronic rhinosinusitis without nasal polyps and in patients who fail standard sprays before surgery or biologic treatment.

FAQs

Is OPN-375 the same as XHANCE?

Yes. OPN-375 is the development designation for XHANCE, Optinose's fluticasone propionate product using the Exhalation Delivery System.

Is XHANCE a biologic?

No. XHANCE is a small-molecule corticosteroid drug-device combination. Biosimilar approval rules do not apply.

Can a generic company copy XHANCE?

A generic company may seek approval through an ANDA or a 505(b)(2) application, but it would need to address the delivery device, formulation, therapeutic equivalence, and applicable patents.

Does XHANCE compete with Dupixent?

Yes, primarily in patients with chronic rhinosinusitis with nasal polyps. XHANCE is a topical, noninjectable treatment, while Dupixent is a systemic biologic used mainly in more severe disease.

What is the main commercial catalyst for XHANCE?

The main catalyst is broader adoption of the chronic rhinosinusitis without nasal polyps indication, particularly among patients who have inadequate control with conventional intranasal corticosteroid sprays.

References

1. U.S. Food and Drug Administration. (2017). FDA approves XHANCE for nasal polyps in adults. FDA.

2. U.S. Food and Drug Administration. (2023). XHANCE prescribing information. FDA.

3. Optinose, Inc. (2019). Annual report on Form 10-K. U.S. Securities and Exchange Commission.

4. Optinose, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.

5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

6. ClinicalTrials.gov. (2023). Clinical studies evaluating fluticasone propionate delivered by the Exhalation Delivery System in chronic rhinosinusitis. U.S. National Library of Medicine.